P785 The prevalence of inflammatory bowel disease doubled in the last decade in Israel: an epiIIRN national population-based study
M. Friedman1,2, D. Navon1, N. Asayag1, G. Focht1, I. Brufman3, B. Feldman3, A. Cahan4, N. Ledderman5, E. Matz6, Y. Chowers7, R. Eliakim8, S. Ben-Horin8, S. Odes9, D. Schwartz9, I. Dotan10, E. Israeli11, R. D. Balicer3, D. Turner*1, Israeli IBD Research Nucleus (IIRN)1
1Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel, 2The Hebrew University- Hadassah Medical Center, Braun School of Public and Community Medicine, Jerusalem, Israel, 3Clalit Health Services, Clalit Research Institute, Chief’s Office, Tel Aviv, Israel, 4Maccabi Healthcare Services, Tel Aviv, Israel, 5Meuhedet Health Services, Tel Aviv, Israel, 6Leumit Health Services, Tel Aviv, Israel, 7Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel, 8Chaim Sheba Medical Center, Department of Gastroenterology, Tel Hashomer, Israel, 9Faculty of Health Sciences,Ben-Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel, 10Rabin Medical Center, Division of Gastroenterology, Petah Tivka, Israel, 11Hadassah Medical Center, Hebrew University, Institute of Gastroenterology and Liver Diseases, Jerusalem, Israel
Although inflammatory disease (IBD) prevalence is particularly high in Jews, the epidemiology of the disease in Israel is largely unknown. Following the validation of case-ascertainment algorithms for the epiIIRN registry, we retrieved IBD cases from all four Israeli HMOs’ databases to calculate national epidemiology trends of IBD in Israel.
Basic demographics of IBD cases identified for the time period 1 January 2003–31 January 2017 were retrieved. Date of diagnosis and IBD type (Crohn’s disease (CD) vs. ulcerative colitis (UC)) were determined by previously validated algorithms. Age- and sex-standardised rates were derived from the Israeli Central Bureau of Statistics; time trends were calculated by Kendall’s Tau-b statistic.
As of January 2017, a total of 42,022 IBD patients were residing in Israel (prevalence 0.5%), of whom, 37770 (90%) were Jews, 3085 (7%) Arabs, and 1169 (3%) unknown. Of the 42022 patients, 0.11% were 0–5 years of age, 0.26% were 6–9 years, 2.4% were 10–16 years, 38% were 17–39 years, 55% were 40–79 years and the others were >80 years. Since 2003, the Jewish prevalence doubled (0.31 to 0.59%) and the Arab prevalence increased threefold (0.06% to 0.17%). During 2006–2016, 19378 patients were newly diagnosed with IBD, of whom 23 (0.11%) were diagnosed at the age of 0–1 years, 122 (0.63%) at 2–5 years, 280 (1.4%) at 6–9 years, 1907 (9.8%) at 10–16 years, 9820 (50.7%) at 17–39 years and 7226 (37.3%) ≥40 years. Adjusted prevalence of CD and UC per 100000 were 313 and 271 among Jews, and 79 and 94 among Arabs, respectively, indicating that UC predominates only in the Arab population (Graph 1).
Israeli IBD prevalence trends.
While males slightly predominated in the entire cohort (50.4% vs. 49.6%;
IBD prevalence in Israel continues to increase, as does IBD incidence in children, and now affects 0.5% of the population. This study was supported by a grant from the Leona M. and Harry B. Helmsley Charitable Trust.